EyeConic: Qualification for Cone-Optogenetics
Qualification for Cone-Optogenetics (EyeConic)
1 other identifier
observational
1,000
7 countries
9
Brief Summary
This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2021
Longer than P75 for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2021
CompletedFirst Submitted
Initial submission to the registry
February 16, 2022
CompletedFirst Posted
Study publicly available on registry
March 24, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
July 31, 2025
July 1, 2025
5.4 years
February 16, 2022
July 28, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
OCT - Central retinal volume
Number of participants with preserved central retinal volume
Baseline (about 10 minutes)
Study Arms (2)
Patients
-Availability of macular optical coherence tomography (OCT)
Controls
-Availability of macular optical coherence tomography (OCT)
Interventions
Data of macular optical coherence tomography (OCT)
Eligibility Criteria
* Patients with diagnosis of generalized retinal dystrophy * Normal controls
You may qualify if:
- Diagnosis of generalized IRD
- Low vision as defined as visual acuity worse or equal to 0.05 (or 20/400) in the study eye
- Availability of macular optical coherence tomography (OCT)
- Normal ophthalmic findings
- Availability of macular optical coherence tomography (OCT)
You may not qualify if:
- Other eye diseases with a significant effect on vision or retinal structure
- Extraocular disease affecting retinal structure such as neurodegenerative diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (9)
University of California San Francisco, Department of Ophthalmology
San Francisco, California, 94158, United States
Bascom Palmer Eye Institute
Miami, Florida, 33136, United States
University of Pittsburgh, Department of Ophthalmology
Pittsburgh, Pennsylvania, 15213, United States
Beijing Institute of Ophthalmology
Beijing, China
Universitätsklinikum Tübingen Augenklinik
Tübingen, Germany
Semmelweis University, Department of Ophthalmology
Budapest, Hungary
Oculista Ospedale Parma
Parma, Italy
University Hospital Basel, Eye Clinic
Basel, 4031, Switzerland
Moorfields Eye Hospital
London, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nicolas Feltgen, MD
University Hospital Basel/Institute of Molecular and Clinical Ophthalmology Basel, Switzerland
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 16, 2022
First Posted
March 24, 2022
Study Start
July 1, 2021
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
July 31, 2025
Record last verified: 2025-07